What is the role of finerenone in the treatment of chronic kidney disease (CKD)?

Updated: Jul 21, 2021
  • Author: Pradeep Arora, MD; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

In the FIDELIO-DKD trial of finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, significant reductions in adverse renal and cardiovascular outcomes were seen in patients with type 2 diabetes and CKD. After a median follow-up of 2.6 years, finerenone was associated with a 3.4% absolute reduction in the rate of kidney failure, renal death, and a drop in estimated glomerular filtration rate (eGFR) of at least 40% from baseline. [61]  Those results suggest the possibility of triple therapy with a RAS inhibitor, an SGLT2 inhibitor, and finerenone for DKD. [62]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!